Brain metastases remain one of the most clinically significant complications in patients with advanced non-small cell lung cancer (NSCLC), occurring in up to 20% of cases and even more frequently in molecularly defined subgroups such as EGFR-mutant or ALK-rearranged disease. These metastases are associated with reduced survival, impaired neurocognitive function, and substantial deterioration in quality of life.
Despite advances in systemic therapies, including targeted agents and immunotherapy, intracranial disease continues to represent a major site of treatment failure. Strategies aimed at preventing brain metastases are therefore of considerable clinical interest. Prophylactic cranial irradiation (PCI), widely used in small-cell lung cancer, has not been routinely adopted in NSCLC due to previously inconsistent survival benefits.
The PRoT-BM trial was designed to evaluate whether PCI could reduce the incidence of brain metastases and improve long-term outcomes in patients with high-risk metastatic NSCLC.
Inside the PRoT-BM Trial: How the Study Was Designed
PRoT-BM is an open-label, single-center, phase II randomized trial conducted in Mexico. Patients with stage IIIB/IV NSCLC at high risk for brain metastases and no baseline central nervous system involvement were randomized in a 1:1 ratio to receive either PCI plus standard systemic therapy or standard therapy alone.
PCI was delivered at a dose of 25 Gy in 10 fractions. The primary endpoint was the cumulative incidence of brain metastases at 24 months, while secondary endpoints included overall survival (OS), neurocognitive function, and leptomeningeal disease incidence.
A total of 84 patients were enrolled, with 81 included in the final efficacy analysis (38 in the PCI group and 43 in the control group). The median follow-up duration exceeded six years, allowing for robust long-term outcome assessment.
Radiotherapy For Early Stage Non-Small Lung Cancer
PCI Significantly Reduces Brain Metastases Risk
The study demonstrated a significant and durable reduction in the risk of brain metastases with PCI. The hazard ratio for brain metastasis was 0.40, corresponding to a 60% relative risk reduction.
At five years, the cumulative incidence of brain metastases was markedly lower in the PCI group compared to the control group (51.7% vs. 78.3%). Additionally, PCI significantly prolonged the median brain-metastasis-free interval from 29.4 months to 59.1 months.
These findings confirm that PCI not only delays but substantially reduces intracranial disease burden over time.
Overall Survival Benefit
A key finding of the PRoT-BM analysis is the observed improvement in overall survival. Median OS was 30.51 months in the PCI group compared to 19.23 months in the control group, corresponding to a hazard ratio of 0.46.
This translates into an 11-month survival benefit and a 54% reduction in the risk of death. Notably, long-term survival outcomes also favored PCI, with five-year survival rates increasing from 7% in the control arm to 23% in the PCI arm.
These results are particularly noteworthy, as previous studies evaluating PCI in NSCLC have generally failed to demonstrate a survival advantage.
Does PCI Affect Cognitive Function?
Concerns regarding potential neurotoxicity have historically limited the use of PCI. However, long-term neurocognitive assessments in this study provide reassuring evidence.
Neurocognitive function, measured using the Mini-Mental State Examination (MMSE), remained stable and comparable between treatment groups during the first two years of follow-up. At later time points, patients in the PCI group demonstrated more stable cognitive trajectories compared to controls.
Importantly, there was no evidence of progressive radiation-induced neurotoxicity over extended follow-up. These findings suggest that effective intracranial disease control may contribute to preserving cognitive function.
What About Leptomeningeal Spread?
Leptomeningeal metastases were relatively uncommon in both groups. Although the incidence was numerically lower in the PCI arm (11.5% vs. 17.4%), this difference did not reach statistical significance.
While these findings are exploratory, they suggest a potential role for PCI in reducing leptomeningeal dissemination, warranting further investigation.
Where Does PCI Fit in Modern NSCLC Treatment?
The results of the PRoT-BM trial should be interpreted within the evolving landscape of NSCLC treatment. The introduction of third-generation tyrosine kinase inhibitors and immunotherapy has improved systemic and intracranial disease control. However, access to these therapies remains limited in many settings.
In this context, PCI may represent a pragmatic and cost-effective strategy to reduce brain metastases, particularly in resource-constrained environments. Additionally, even in settings where advanced systemic therapies are available, PCI could provide incremental benefit in carefully selected high-risk patients.
The observed survival benefit in this trial may reflect improved patient selection, particularly the inclusion of molecularly high-risk populations, as well as longer follow-up allowing survival differences to emerge.
What Are the Study Limitations?
Several limitations should be acknowledged. The study was conducted at a single center with a relatively small sample size, which may limit generalizability. Additionally, systemic treatment strategies evolved during the study period, and not all patients received contemporary therapies such as third-generation TKIs or immunotherapy.
Should PCI Be Reconsidered in NSCLC?
The final analysis of the PRoT-BM trial demonstrates that prophylactic cranial irradiation significantly reduces the incidence of brain metastases and provides a meaningful overall survival benefit in patients with high-risk metastatic NSCLC.
Importantly, these benefits were achieved without evidence of long-term neurocognitive decline, supporting the safety of this approach.
While these findings are promising, confirmation in larger, multicenter phase III trials is required before PCI can be considered a standard strategy in this patient population.
Read full article here
Stay informed with more articles like this on OncoDaily.
Written by Nare Hovhannisyan,MD